From: Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index
Citation | Number | Study Design | Instrument | Results of Symptom and/or HRQL assessment |
---|---|---|---|---|
MRC Renal Cancer 1999 [8] | N = 335 | Randomized | Rotterdam Symptom Checklist | Most frequent symptoms at 4 weeks: tired (57%), lack of energy (53%), lack of appetite (33%), dry mouth (27%), nausea (15%), shivering (13%), heartburn (12%) |
Motzer et al. 2000 [9] | N = 284 | Randomized | FACT-BRM | QOL decreased from baseline to 8 weeks for treatment arms. Item analysis of FACT-BRM indicates items that address the following likely to be important at baseline: energy, pain, sex life, overall well-being, sleep, fatigue, appetite, energy, weakness (Cella D, personal communication, September 2003) |
Capuron et al. 2001 [10] | N = 33 | Non-randomized | MADRS | Positive correlation between depressive symptoms and the variation in the cytokine levels in the first week of therapy. |
Heinzer et al. 1999 [11] | N = 20 | Non-randomized | EORTC-QLQ-30 | Most frequent symptoms: fatigue (29%), nausea (23%), cough (16%). |
Atzpodien et al. 2003 [12] | N = 22 | Observational | SF-36 EORTC-QLQ-30 | Significant worsening in physical, social, and role functioning. Significant worsening in symptoms of appetite loss, nausea/vomiting, sleep disturbance, diarrhea, pain |
Bukowski et al. 2002 [13] | N = 70 | Observational | AE events | Most frequently reported adverse events over 1 year: fatigue (38%), anorexia (34%), pain (34%), headache (31%), myalgia (28%), weight loss (28%), nausea (24%), alopecia (21%), coughing: (21%), dyspnea (21%), fever (21%), rigors (21%) |
Cohen et al. 2002 [14] | N = 36 | Observational | SF-36 | Changes from baseline to 3 weeks indicate improvement in physical functioning, role limitations (physical), bodily pain, vitality, and social functioning |
Joffe et al. 1996 [15] | N = 55 | Observational | Rotterdam Symptom Checklist | During 8-week treatment cycle, significant worsening in symptoms: loss of appetite, dry mouth, lack of energy, feeling nervous, lack of sexual interest, shivering, nausea, tiredness |
Naglieri et al. 2002 [16] | N = 42 | Observational | Graded toxicities | Total prevalence: fatigue (100%), cutaneous erythema (100%), fever (76%), anemia (10%), hypotension (5%), nausea/vomitting (2%), fluid retention (2%) |
Shamash et al. 2003 [17] | N = 33 | Observational | EORTC | Mean baseline scores indicate greatest impairment in pain, sleep, weakness, daily activities, tired, leisure/social |
Stark et al. 2002 [18] | N = 178 | Observational | HAD-A EORTC-QLQ-30 | Patients diagnosed with anxiety had higher scores for symptoms of fatigue, nausea, insomnia, appetite loss, constipation, diarrhea |
Whitehead et al. 2002 [19] | N = 37 | Observational | Graded toxicity | Most common side effects (% with any grade toxicity): nausea/vomiting/diarrhea: 88%, headache/pain: 82%, malaise/fatigue/lethargy: 78%, fever/chills: 57%, edema: 51%, CNS: 43%, anemia/bleeding: 33%, myalgia/arthralgia: 31%, renal: 29%, pulmonary: 27%, rash/urticaria: 24%, hypertension: 8%, cardiac: 4%, hypotension: 4% |